Studies on the effectiveness of chemotherapy in patients with MSI-H tumours
| Author, year | Type of study and selection criteria | Agents | Patients with MSI-H tumour | Effect of chemotherapy |
|---|---|---|---|---|
| CRC, colorectal cancer; FU, fluorouracil; HNPCC, hereditary non-polyposis colorectal cancer; MSI, microsatellite instability; RCT, randomised controlled trial. | ||||
| Liang et al,55 2002 | Prospective, non-randomised; stage IV CRC | High-dose 5-FU/leucovorin | 52 | Better survival in patients with MSI-H tumours who received chemotherapy |
| Ribic et al,56 2003 | Retrospective MSI analysis of tumours from patients who participated in a multicentre RCT 20–25 years ago; CRC stage II/III | 5-FU/leucovorin or levamisol | 95 | No survival differences |
| Carethers et al,57 2004 | Retrospective, consecutive patients; CRC stage II/III | 5-FU-based | 36 | No survival differences |
| De Vos et al,58 2004 | Retrospective, CRC stage III patients from families with HNPCC | 5-FU/leucovorin or levamisol | 92 | No survival differences |
| Fallik et al,59 2003 | Non-randomised controlled trial; CRC stage IV | Irinotecan (CPT11) | 7 | 3 partial and 1 complete response |